Article

Gregory J. Riely on MET Exon 14 Skipping Mutations in Lung Cancer

Author(s):

Gregory J. Riely

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of MET exon 14 skipping mutations in lung cancer.

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of MET exon 14 skipping mutations in lung cancer.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man.
Delving into the Evaluation of JNJ-1900 Trial for Lung Cancer Treatment
Minimally invasive screening methods offer a more accessible, cost-effective way to detect Barrett’s esophagus early and help prevent esophageal cancer.
Expanding Access to Screening May Help Prevent Esophageal Cancer
A variant in the IL-7 gene may predict which patients with kidney cancer are more likely to experience side effects from immunotherapy.
Gene Variant May Predict Side Effects From Kidney Cancer Immunotherapy
Image of Dr. Tiziano Barbui
How Essential Thrombocythemia and Polycythemia Vera Affect Blood Flow
Image of Dr. Merrell
IDH Inhibitors Offer New, Safer Option for Some Brain Tumors
Image of Dr. Evens.
Uniting Pediatric and Adult Oncologists to Advance AYA Lymphoma Care
Avoiding smoking, eating a high-fiber diet and routine screenings are key to reducing the risk of recurrence in colorectal or anal cancer.
Expert Offers Surveillance, Lifestyle Guidance After CRC, Anal Cancer
Image of Dr. D'sa
Understanding the Evolution of Waldenström Macroglobulinemia Treatment
Image of doctor.
Early Arterial Thrombosis May Signal Future Cancer Risk
Image of Dr. Deville.
What are the Long-Term Side Effects of Proton Therapy in Prostate Cancer?
Related Content
fda image.
May 29th 2025

Patritumab Deruxtecan BLA Withdrawn in Non-Small Cell Lung Cancer

Ryan Scott
The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in the U.S. has been withdrawn.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of lungs.
May 28th 2025

Phase 1/2 Trial Investigating ATR-04 for EGFRi-Related Rashes in Lung Cancer

Ryan Scott
ATR-04 therapy is being investigated in the phase 1/2 ATR04-484 clinical trial for the treatment of EGFR inhibitor-associated rashes in lung cancer.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
First-line Zepzelca plus Tecentriq led to survival improvements versus Tecentriq alone in patients with ES-SCLC: © stock.adobe.com.
May 22nd 2025

Zepzelca Plus Tecentriq Boosts Survival in First-Line ES-SCLC Care

Kristi Rosa
Among patients with ES-SCLC, first-line maintenance therapy with Zepzelca plus Tecentriq led to improvements in PFS and OS versus Tecentriq alone.
Image of lungs.
May 21st 2025

FDA Grants Fast Track Designation to ZL-1310 in Small Cell Lung Cancer

Spencer Feldman
ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage in most patients treated.